331 related articles for article (PubMed ID: 32553774)
1. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience.
Yang Z; Wang S; Tian XY; Xie QF; Zhuang L; Li QY; Chen CZ; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):365-370. PubMed ID: 32553774
[TBL] [Abstract][Full Text] [Related]
2. Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
Invernizzi F; Iavarone M; Zavaglia C; Mazza S; Maggi U; Cesarini L; Antonelli B; Airoldi A; Manini MA; Sangiovanni A; Rossi G; Donato MF; Saverio Belli L; Lampertico P
Transplantation; 2020 Mar; 104(3):568-574. PubMed ID: 31517781
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
[TBL] [Abstract][Full Text] [Related]
4. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N; Landi F; Carra MC; Azoulay D
World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
[TBL] [Abstract][Full Text] [Related]
5. Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics.
Bodzin AS; Lunsford KE; Markovic D; Harlander-Locke MP; Busuttil RW; Agopian VG
Ann Surg; 2017 Jul; 266(1):118-125. PubMed ID: 27433914
[TBL] [Abstract][Full Text] [Related]
6. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome.
Wu TJ; Chan KM; Chou HS; Lee CF; Wu TH; Chen TC; Yeh CT; Lee WC
Ann Surg Oncol; 2013 Oct; 20(11):3582-90. PubMed ID: 23760589
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation.
Cheng YC; Chen TW; Fan HL; Yu CY; Chang HC; Hsieh CB
Ann Transplant; 2014 Jun; 19():309-16. PubMed ID: 24975583
[TBL] [Abstract][Full Text] [Related]
8. Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation.
Chan KM; Yu MC; Chou HS; Wu TJ; Lee CF; Lee WC
Ann Surg Oncol; 2011 Sep; 18(9):2638-46. PubMed ID: 21584831
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Sorafenib After Liver Transplantation: Experience in Our Center.
López Ortega S; González Grande R; Santaella Leiva I; De la Cruz Lombardo J; Jiménez Pérez M
Transplant Proc; 2020 Mar; 52(2):540-542. PubMed ID: 32057495
[TBL] [Abstract][Full Text] [Related]
10. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study.
Wang ZY; Tao QF; Wang ZH; Lin KY; Huang G; Yang Y; Zhou WP; Lau WY
Am J Surg; 2020 Apr; 219(4):717-725. PubMed ID: 31266631
[TBL] [Abstract][Full Text] [Related]
11. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?
Adam R; Azoulay D; Castaing D; Eshkenazy R; Pascal G; Hashizume K; Samuel D; Bismuth H
Ann Surg; 2003 Oct; 238(4):508-18; discussion 518-9. PubMed ID: 14530722
[TBL] [Abstract][Full Text] [Related]
12. Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis.
Sapisochin G; Castells L; Dopazo C; Bilbao I; Minguez B; Lázaro JL; Allende H; Balsells J; Caralt M; Charco R
Ann Surg Oncol; 2013 Apr; 20(4):1194-202. PubMed ID: 22965574
[TBL] [Abstract][Full Text] [Related]
13. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
[TBL] [Abstract][Full Text] [Related]
14. Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy.
Fields TD; Philips P; Scoggins CR; Tatum C; Kelly L; McMasters KM; Martin RCG
World J Surg; 2017 May; 41(5):1331-1339. PubMed ID: 27905019
[TBL] [Abstract][Full Text] [Related]
15. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
16. Treatment of recurrent hepatocellular carcinoma after liver transplantation.
Kim HR; Cheon SH; Rha SY; Lee S; Han KH; Chon CY; Lee JD; Sung JS; Chung HC
Asia Pac J Clin Oncol; 2011 Sep; 7(3):258-69. PubMed ID: 21884437
[TBL] [Abstract][Full Text] [Related]
17. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.
Iavarone M; Invernizzi F; Czauderna C; Sanduzzi-Zamparelli M; Bhoori S; Amaddeo G; Manini MA; López MF; Anders M; Pinter M; Rodríguez MJB; Cristóbal MR; Soteras GA; Piñero F; Villadsen GE; Weinmann A; Crespo G; Mazzaferro V; Regnault H; Giorgio M; González-Diéguez ML; Donato MF; Varela M; Wörns MA; Bruix J; Lampertico P; Reig M
Am J Transplant; 2019 Nov; 19(11):3176-3184. PubMed ID: 31365177
[TBL] [Abstract][Full Text] [Related]
18. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant.
Satapathy SK; Das K; Kocak M; Helmick RA; Eason JD; Nair SP; Vanatta JM
Clin Transplant; 2018 May; 32(5):e13246. PubMed ID: 29577449
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study.
Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G
Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
